Studies ravulizumab early in antibody-positive generalized myasthenia gravis
Observes ravulizumab use in adults with early antibody-positive generalized myasthenia gravis.
Plain-language title generated from the registry record
Registry title: Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
Key facts
- Where
- Bergamo, Bologna, Brescia, Florence, Imperia, Lecco, Messina, Milan, Naples, Novara, Orbassano, Padova, Palermo, Parma, Pavia, Pisa, Roma, Salerno, San Giovanni Rotondo, Sassari, and Torino, ItalySee the 21 sites
Where in Italy
- BergamoBergamo, ItalyTaking people
- BolognaBologna, ItalyNot yet recruiting
- BresciaBrescia, ItalyTaking people
- FlorenceFlorence, ItalyTaking people
- ImperiaImperia, ItalyNot yet recruiting
- LeccoLecco, ItalyTaking people
- MessinaMessina, ItalyNot yet recruiting
- MilanMilan, ItalyTaking people
- NaplesNaples, ItalyNot yet recruiting
- NovaraNovara, ItalyNot yet recruiting
- OrbassanoOrbassano, ItalyNot yet recruiting
- PadovaPadova, ItalyNot yet recruiting
- PalermoPalermo, ItalyNot yet recruiting
- ParmaParma, ItalyTaking people
- PaviaPavia, ItalyNot yet recruiting
- PisaPisa, ItalyNot yet recruiting
- RomaRoma, ItalyNot yet recruiting
- SalernoSalerno, ItalyNot yet recruiting
- San Giovanni RotondoSan Giovanni Rotondo, ItalyTaking people
- SassariSassari, ItalyTaking people
- TorinoTorino, ItalyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alexion Pharmaceuticals, Inc.
- Trial code
- NCT06967480
- Record updated
- 5 February 2026
- Original description
The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.Read full original descriptionShow less
MG-EVOLUTION. Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis: A Real-World Study With Biomarker Analysis
The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.
Inclusion: Diagnosis of MG confirmed by:; History of a positive serologic test for anti-AChR antibodies, and; One of the following:; History of abnormal neuromuscular transmission test demonstrated by singlefibre electromyography or repetitive nerve stimulation; History of positive anticholinesterase test (e.g., edrophonium chloride test); or; Patient demonstrated improvement in MG signs on oral cholinesterase inhibitors, as assessed by the treating physician; Disease duration from MG onset ≤ 3 years before T-4 (Enrolment); MGFA class IIb to IV; Patient eligible for Ravulizumab treatment based on AIFA reimbursement criteria; Vaccination cycle for Neisseria meningitidis completed at least two weeks before Ravulizumab initiation or antibiotics chemoprophylaxis according to the SmPC.
Exclusion: Previous treatment with C5 inhibitors; Last rituximab infusion performed < 6 months before T-4 (Enrolment); Last infusion with FcRn blockers performed < 3 months before T-4 (Enrollment); Previous or current participation to other interventional studies; Hypersensitivity to the active substance or to any of the excipients of the study product; Patient unable to understand and sign the informed consent; Patient for whom the study product is contraindicated according to SmPC; Pregnant or lactating or planning a pregnancy during the study; Patient who plan to relocate during the study; Patient who are unsure of following the visit schedule; Patient unable to complete questionnaires.